Kamada Ltd (KMDA) SEC Filings — 2025

Filings

• Kamada Ltd. Extends Canadian Supply Tender by $10-14M — 6-K · Dec 18, 2025
• Kamada Ltd. Holds Annual Shareholder Meeting — 6-K · Dec 10, 2025
• Kamada Discontinues Phase 3 Trial, Still Eyes 2026 Growth — 6-K · Dec 8, 2025
• Kamada Ltd. Files 6-K with Q3 & 9-Month 2025 Results — 6-K · Nov 10, 2025
• Kamada Ltd 6-K Filing — 6-K · Nov 4, 2025
• Kamada Ltd. Sets December 10th Annual Shareholder Meeting — 6-K · Oct 23, 2025
• Kamada Ltd. to Attend September Investor Conferences — 6-K · Sep 2, 2025
• Kamada Ltd. Reports Strong Q2 and H1 2025 Financial Results — 6-K · Aug 13, 2025
• Kamada Ltd. Secures FDA Approval for Houston Plasma Center — 6-K · Aug 11, 2025
• Kamada Ltd. to Report Q2 2025 Financials Aug 13 — 6-K · Aug 6, 2025
• Kamada Ltd. Confirms Global Operations and Product Availability — 6-K · Jun 17, 2025
• Kamada Ltd. Files Q1 2025 Results, Incorporates into S-8 Filings — 6-K · May 14, 2025
• Kamada Ltd. to Report Q1 2025 Results on May 14 — 6-K · May 7, 2025
• Kamada Launches Post-Marketing Research for CYTOGAM — 6-K · May 5, 2025
• Kamada Ltd. Updates on Dividend Tax Procedures — 6-K · Mar 24, 2025
• Kamada Ltd. Expands Plasma Collection with New Texas Site — 6-K · Mar 19, 2025
• Kamada Ltd. Files 2024 Annual Report — 20-F · Mar 5, 2025
• Kamada Ltd. to Report Q4 & FY2024 Results March 5 — 6-K · Feb 26, 2025
• Kamada Secures $25M Latin America Supply Deal — 6-K · Jan 22, 2025
• Kamada Ltd. Affirms 2024 Guidance, Eyes Double-Digit Growth in 2025 — 6-K · Jan 8, 2025